↓ Skip to main content

Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics

Overview of attention for article published in Drug Safety, March 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
4 X users

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
65 Mendeley
Title
Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics
Published in
Drug Safety, March 2018
DOI 10.1007/s40264-018-0660-4
Pubmed ID
Authors

David L. Murphy, Jacob A. Lebin, Stevan G. Severtson, Heather A. Olsen, Nabarun Dasgupta, Richard C. Dart

Abstract

The epidemic of prescription opioid overdose and mortality parallels the dispensing rates of prescription opioids, and the availability of increasingly potent opioid analgesics. The common assumption that more potent opioid analgesics are associated with higher rates of adverse outcomes has not been adequately substantiated. We compared the rate of serious adverse events among commonly prescribed opioid analgesics of varying potency. Serious adverse events (SAEs; defined as death, major medical effect, or hospitalization) resulting from exposure to tablets containing seven opioid analgesics (oxycodone, hydrocodone, morphine, hydromorphone, oxymorphone, tapentadol, and tramadol) captured by the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System Poison Center Program were evaluated from 2010 through 2016. Rates of SAEs were adjusted for availability through outpatient dispensing data and regressed on morphine milligram equivalents (MME). There were 19,480 cases of SAE during the 7-year study period. Hydrocodone and oxycodone contributed to 77% of SAE cases. Comparing rates of outcome by relative potency, a hierarchy was observed with hydromorphone (8.02 SAEs/100 kg) and tapentadol (0.27 SAE/100 kg) as the highest and lowest rates, reflecting a 30-fold difference among individual opioid products. SAE rate and potency were related linearly-SAEs increased 2.04 per 100 kg drug dispensed for each 1-unit rise in MME (p = 0.004). Linear regression of SAE/100 kg drug dispensed and drug potency identified that MME comprised 96% of the variation observed. In contrast, potency did not explain variation seen using other study denominators (prescriptions dispensed, dosage units dispensed, and the number of individuals filling a prescription). Potency of a prescription opioid analgesic demonstrates a significant, highly positive linear relationship with exposures resulting in SAEs per 100 kg drug dispensed reported to poison centers. Potency should be carefully considered from both individual provider and public health perspectives.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 65 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 17%
Researcher 10 15%
Other 8 12%
Student > Bachelor 6 9%
Student > Postgraduate 6 9%
Other 11 17%
Unknown 13 20%
Readers by discipline Count As %
Medicine and Dentistry 27 42%
Pharmacology, Toxicology and Pharmaceutical Science 13 20%
Nursing and Health Professions 4 6%
Neuroscience 2 3%
Immunology and Microbiology 1 2%
Other 4 6%
Unknown 14 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2018.
All research outputs
#1,378,642
of 23,063,209 outputs
Outputs from Drug Safety
#125
of 1,705 outputs
Outputs of similar age
#32,906
of 330,425 outputs
Outputs of similar age from Drug Safety
#7
of 33 outputs
Altmetric has tracked 23,063,209 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,705 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,425 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.